Researchers from BeiGene presented data on the discovery of highly selective covalent tyrosine-protein kinase BTK inhibitors for the potential treatment of B-cell malignancies and autoimmune disorders. Read More

Hypomyelinating leukodystrophy is a genetic disorder characterized by deficient myelination of the central nervous system white matter. An international team of researchers has published a case report of 4 unrelated families with a hypomyelinating leukodystrophy phenotype. Read More

Researchers have created mouse embryos entirely from stem cells in vitro that formed a brain and a beating heart and lay the foundations for all the other organs of the body. The synthetic embryos faithfully mimic the development of their natural counterparts in utero for 8.5 days, before hitting a roadblock and becoming disorganized. Read More

The Broad Institute, Janssen Biotech and Massachusetts General Hospital have divulged new serine/threonine-protein kinase SIK2 (QIK) inhibitors reported to be useful for the treatment of cancer and autoimmune disease. Read More

Lapix Therapeutics has described new tartaric acid analogues acting as immune checkpoint inhibitors reported to be useful for the treatment of cancer. Read More

Blueprint Medicines has identified new cAMP-dependent protein kinase catalytic subunit alpha (PRKACA) inhibitors reported to be useful for the treatment of Carney complex (NAME syndrome, LAMB syndrome), McCune-Albright syndrome, polycystic kidney disease and cancer. Read More

Txinno Bioscience has presented benzotriazole derivatives acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (E-NPP 1) inhibitors reported to be useful for the treatment of cancer. Read More

Regulatory T cells (Tregs) are contributors of tumor immune evasion; Ikaros family zinc finger protein 2 (IKZF2) plays a crucial role in the maintenance of function and stability of Tregs. IKZF2-deificent tumoral Tregs produce inflammatory cytokines and enhance antitumoral immunity in mice. Read More

In the search for novel antibacterial agents, some targets have been engaged to kill Gram-positive but not Gram-negative organisms, due to lack of accumulation of proposed agents. Read More

The FDA has cleared Century Therapeutics' IND application to commence a phase I study of CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies. Read More

he continuing emergence of immune-evasive variants of SARS-CoV-2 virus represents a major challenge in controlling COVID-19 pandemic disease. Researchers from Stanford University have tested the immunogenicity and protective effect of the receptor binding domain (RBD)-I53-50 AS03-adjuvanted nanoparticle vaccine in nonhuman primates. Read More